These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37243089)

  • 1. Real-World Effectiveness of Four Types of COVID-19 Vaccines.
    Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Meslamani AZA; Hayajneh W; Alwahadneh AM; Hamadi S; Abu-Qatouseh L; Awad R; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Asad M; AbuRuz S
    Vaccines (Basel); 2023 May; 11(5):. PubMed ID: 37243089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.
    Ezzikouri S; Tajudeen R; Majidi H; Redwane S; Aqillouch S; Abdulaziz M; Aragaw M; Papa Fallah M; Sembuche S; Batcho S; Kabwe P; Gonese E; Laazaazia O; Elmessaoudi-Idrissi M; Meziane N; Ainahi A; Sarih M; Ogwell Ouma AE; Maaroufi A
    Sci Rep; 2024 Apr; 14(1):7817. PubMed ID: 38570577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of BNT162b2, BBIBP-CorV, Gam-COVID-Vac and ChAdOx1 nCoV-19 Vaccines Six Months after the Second Dose: A Longitudinal Prospective Study.
    Petrović V; Vuković V; Patić A; Marković M; Ristić M
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines.
    Kokić Z; Kon P; Djurković-Djaković O
    Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.
    Batmunkh T; Moore KA; Thomson H; Altangerel B; Amraa O; Avaa N; Batbayar L; Batsukh K; Bright K; Burentogtokh T; Ha Do LA; Dorj G; Hart JD; Javkhlantugs K; Jigjidsuren S; Justice F; Li S; Licciardi PV; Mashbaatar K; Mazarakis N; Neal EFG; Nguyen CD; Ochirbat B; Tsolmon B; Tuya A; Surenjav U; von Mollendorf C; Mulholland K
    Lancet Reg Health West Pac; 2024 Jan; 42():100953. PubMed ID: 38357398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
    Rearte A; Castelli JM; Rearte R; Fuentes N; Pennini V; Pesce M; Barbeira PB; Iummato LE; Laurora M; Bartolomeu ML; Galligani G; Del Valle Juarez M; Giovacchini CM; Santoro A; Esperatti M; Tarragona S; Vizzotti C
    Lancet; 2022 Mar; 399(10331):1254-1264. PubMed ID: 35303473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.
    Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A
    Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    Theresa Pool SN; Shroff EH; Chetty A; Lewis L; Nonhlanhla YZ; Abdool Karim SS
    PLoS One; 2024; 19(4):e0299747. PubMed ID: 38578809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RBD-specific antibody response after two doses of different SARS-CoV-2 vaccines during the mass vaccination campaign in Mongolia.
    Batmunkh B; Otgonbayar D; Shaarii S; Khaidav N; Shagdarsuren OE; Boldbaatar G; Danzan NE; Dashtseren M; Unurjargal T; Dashtseren I; Dagvasumberel M; Jagdagsuren D; Bayandorj O; Biziya B; Surenjid S; Togoo K; Bat-Erdene A; Narmandakh Z; Choijilsuren G; Batmunkh U; Soodoi C; Boldbaatar EA; Byambatsogt G; Byambaa O; Deleg Z; Enebish G; Chuluunbaatar B; Zulmunkh G; Tsolmon B; Gunchin B; Chimeddorj B; Dambadarjaa D; Sandag T
    PLoS One; 2023; 18(12):e0295167. PubMed ID: 38064430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report.
    Lijeskić O; Klun I; Stamenov Djaković M; Gligorić N; Štajner T; Srbljanović J; Djurković-Djaković O
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan.
    Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Al Meslamani AZ; Hayajneh W; Ata OMA; Shnaigat W; AbuRuz S; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Khader K; Hakim T; Hammad FA; Al Qudah M; Asad M
    Clin Drug Investig; 2022 Oct; 42(10):813-827. PubMed ID: 35999428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Antibody Responses Following Vaccination with AstraZeneca and Sinopharm.
    Anvari E; Ghamar Talepoor A; Eshkevar Vakili M; Karimi N; Ataollahi M; Najafi G; Kabelitz D; Ahmadi I; Kalantar K
    Iran J Immunol; 2022 Sep; 19(3):321-329. PubMed ID: 36190385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2.
    Szabó E; Modok S; Rónaszéki B; Faragó A; Gémes N; Nagy LI; Hackler L; Farkas K; Neuperger P; Balog JÁ; Balog A; Puskás LG; Szebeni GJ
    Front Med (Lausanne); 2023; 10():1176168. PubMed ID: 37529238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
    Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
    Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of T cells mediated immunity and side effects of mRNA vaccine and conventional COVID-19 vaccines administrated in Jordan.
    Jaber HM; Ebdah S; Al Haj Mahmoud SA; Abu-Qatouseh L; Jaber YH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2333104. PubMed ID: 38584118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate Adverse Reaction and SARS-CoV-2 Anti-Spike Receptor Binding Domain IgG of COVID-19 Vaccines Among Health Staffs.
    Rasheed WS; Sarkees AN
    Disaster Med Public Health Prep; 2024 Apr; 18():e66. PubMed ID: 38618867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study.
    Bouillon K; Baricault B; Botton J; Jabagi MJ; Bertrand M; Semenzato L; Le Vu S; Drouin J; Dray-Spira R; Weill A; Zureik M
    BMJ Med; 2022; 1(1):e000104. PubMed ID: 36936561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia.
    Petrović V; Vuković V; Marković M; Ristić M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.